Chelsea Therapeutics - Best Pharma Stocks of 2007
Company: Chelsea Therapeutics
Starting stock price: $3.82
Ending stock price: $7.85
Percent Change: 92.41%
Details: Chelsea Therapeutics is developing therapies for a number of inflammatory conditions. In 2007 the company won orphan status for Droxidopa, which treats low blood pressure stemming from Parkinson's or from multiple-system atrophy. The drug already has orphan status in the U.S. and is in Phase III trials. Chelsea also has the drug candidate CH-1504 in Phase II trials for rheumatoid arthritis, psoriasis and inflammatory bowel disease.
More News:
Chelsea wins European orphan status. Report
FDA grants Droxidopa orphan drug status. Report
More stories about Chelsea Therapeutics
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: